Extend telehealth flexibilities to virtual prescribing, mental health services, coalition asks lawmakers
By
Kimberly Bonvissuto
Sep 16, 2024
A coalition of provider and consumer organizations is asking policymakers to extend telehealth flexibilities related to virtual prescribing tied to mental health services.
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Semaglutide reduces risk for MACE in patients with obesity and heart failure
By
Haymarket Media
Aug 28, 2024
MACE, heart failure composite end point, cardiovascular death and all-cause death all improved with semaglutide for patients with versus without heart failure.
Mean cost of bringing new drug to US market Is $879.3 million
Jul 02, 2024
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
ACC: Empagliflozin cuts heart failure hospitalization risk after AMI
Apr 08, 2024
Lower risks for first heart failure hospitalization and total heart failure hospitalization were seen with empagliflozin.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...